Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Cash Flow-to-Debt Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. cash flow-to-debt ratio. Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Cash Flow-to-Debt Ratio of -0.13x as of December 2025, meaning its operating cash flow of CN¥-154.64 Million could theoretically repay 0% of its total liabilities (CN¥1.20 Billion) in one year. Check Hangzhou Bio-Sincerity Pharma-Tech Co.Lt (301096) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
Cash flow-to-debt ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025. Historical debt coverage capacity for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. across 7 annual periods. Check 301096 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Cash Flow-to-Debt Ratio by Year (2019–2025)
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.. For the full cash flow conversion analysis, see Hangzhou Bio-Sincerity Pharma-Tech Co.Lt (301096) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.13x | CN¥-154.64 Million | CN¥1.20 Billion | ▲ +24.7% |
| 2024 | -0.17x | CN¥-195.86 Million | CN¥1.14 Billion | ▼ -286.8% |
| 2023 | 0.09x | CN¥90.45 Million | CN¥984.97 Million | ▼ -84.2% |
| 2022 | 0.58x | CN¥259.41 Million | CN¥447.45 Million | ▲ +142.0% |
| 2021 | 0.24x | CN¥145.42 Million | CN¥607.10 Million | ▲ +40.7% |
| 2020 | 0.17x | CN¥54.36 Million | CN¥319.20 Million | ▼ -76.2% |
| 2019 | 0.72x | CN¥71.47 Million | CN¥99.89 Million | — |